Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Nephrotic Syndrome - Overview
Nephrotic Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Nephrotic Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Nephrotic Syndrome - Companies Involved in Therapeutics Development
Adare Pharma Solutions
APIE Therapeutics Inc
Asahi Kasei Pharma Corp
Bristol-Myers Squibb Co
ChemoCentryx Inc
Energenesis Biomedical Co Ltd
Evergreen Therapeutics Inc
Ninevah Therapeutics SL
Pharmapraxis
Syct Pharma AB
Nephrotic Syndrome - Drug Profiles
abatacept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-1189 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APT-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EG-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ENERGIF-710 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ilacirnon sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mizoribine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NTX-014 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
prednisone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nephrotic Syndrome - Dormant Projects
Nephrotic Syndrome - Product Development Milestones
Featured News & Press Releases
Aug 25, 2021: Syct strengthens IP portfolio - Grant of key European patent covering AP1189
Jun 29, 2020: Syct Pharma has initiated the Phase II clinical study with AP1189 in Nephrotic Syndrome
Jun 02, 2020: Syct Pharma?s clinical trial application for AP1189 in Nephrotic Syndrome approved by the Danish Medical Agency
Mar 31, 2020: Syct Pharma submits clinical trial application for AP1189 in Nephrotic Syndrome
Mar 31, 2020: Syct Pharma investigates the possibility of AP1189 as additiol therapy in hospitalized patients with COVID-19
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Nephrotic Syndrome, 2021
Number of Products under Development by Companies, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development for Nephrotic Syndrome, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Nephrotic Syndrome - Pipeline by Adare Pharma Solutions, 2021
Nephrotic Syndrome - Pipeline by APIE Therapeutics Inc, 2021
Nephrotic Syndrome - Pipeline by Asahi Kasei Pharma Corp, 2021
Nephrotic Syndrome - Pipeline by Bristol-Myers Squibb Co, 2021
Nephrotic Syndrome - Pipeline by ChemoCentryx Inc, 2021
Nephrotic Syndrome - Pipeline by Energenesis Biomedical Co Ltd, 2021
Nephrotic Syndrome - Pipeline by Evergreen Therapeutics Inc, 2021
Nephrotic Syndrome - Pipeline by Ninevah Therapeutics SL, 2021
Nephrotic Syndrome - Pipeline by Pharmapraxis, 2021
Nephrotic Syndrome - Pipeline by SynAct Pharma AB, 2021
Nephrotic Syndrome - Dormant Projects, 2021